Heterogeneity, biodiversity and bioperversity in solid neoplasms

European Journal of Surgical Oncology

Volumn 22, Issue 5, 1996, Pages 469-473

  Rew, David A ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIODIVERSITY; FLOW CYTOMETRY; GENETIC HETEROGENEITY; HISTOCHEMISTRY; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 0029903668     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)92795-X     Document Type: Note

References (35)

1. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumour development. New Engl J Med 1988; 319: 525-32.
2. Soussi T, Caron de Fromental C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990; 5: 945-52.
3. Rew DA. Significance of aneuploidy. Br J Surg 1994; 81: 1416-22.
4. Shackney SE, Smith CA, Pollice AA, et al. Preferred genetic evolutionary sequences in human breast cancer: a case study. Cytometry 1995; 21: 6-13.
5. Rohloff AC, Sakach JM, Shackney SE. Analytical approaches relating genetic evolutionary pathways to prognostic factors. Cytometry 1995; 21: 23-9.
6. Shankey TV, Jin J, Dougherty S, Flanigan RC, Graham S, Pyle JM. DNA ploidy and proliferation heterogeneity in human prostate cancers. Cytometry 1995; 21: 30-9.
7. Shackney SE, Shankey TV. Genetic and phenotypic heterogeneity of human malignancies: finding order in chaos (Review). Cytometry 1995; 21: 2-5.
8. Liebovitch L. An introduction to Chaos in Biology. Keynote Lecture. Int Soc Analytical Cytology XVII Congress 1994.
9. Tannock I. Oral communication: Keynote Address, Int Soc Analyt Cytol XVII Congress 1994.
10. Rennie J. Immortal's enzyme. Sci Am 1994; 271: 8-9.
11. Dang CV. c-Myc oncoprotein function. Biochim Biophys Acta 1991; 1072: 103-13.
12. Vile RG. p53: a gene for all tumours? Br Med J 1993; 307: 1226-7.
13. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993; 262: 1980-1.
14. Kerr JFR, Wyllie AH, Currie AH, Apoplosis, a basic biological phenomenon with wider implications in tissue kinetics. Br J Cancer 1972; 26: 239-45.
15. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 1991; 65: 1097-8.
16. Wyllie AH. Apoptosis (the 1992 Frank Rose memorial lecture). Br J Cancer 1993; 67: 205-8.
17. Poste G. Cellular heterogeneity in malignant neoplasms and the therapy of metastases. Ann NY Acad Sci 1982; 397: 34-48.
18. Wheeless LL, Coon JS, Cox C, et al. Precision of DNA flow cytometry in inter-institutional analyses. Cytometry 1991; 12: 405-12.
19. DeVita VT. The relationship between tumour mass and resistance to chemotherapy. Cancer 1983; 51: 1209-90.
20. Jain RK. Barriers to drug delivery in solid tumours. Sci Am 1994; 271: 42-9.
21. Tannock I. Experimental chemotherapy. In: Tannock I. Hill RP (eds) The Basic Science of Oncology (2nd edn). McGraw Hill, 1992: 338-59.
22. Liu LF. DNA topoisomerase poisons as antitumour drugs. Ann Rev Biochem 1989; 58: 351-75.
23. Smith PJ. Topoisomerase inhibitors: new twists to anticancer drug action. Oncol Today 1991; 3: 4-9.
24. Koshland DE. Molecule of the year: the DNA repair enzyme. (Editorial). Science 1994; 226: 1925-7.
25. Modrich P. Mismatch repair, genetic stability and cancer. Science 1994; 226: 1957-8.
26. Hanawalt PC. Transcription-coupled repair and human disease. Science 1994; 266: 1957-8.
27. Sancar A. Mechanisms of DNA excision repair. Science 1994; 266: 1954-6.
28. Hedley DW. Flow cytometric assays of anticancer drug resistance. Ann NY Acad Sci 1993; 677: 341-53.
29. Kartner N, Ling V. Multidrug resistance and Cancer. Sci Am 1989; 260: 26-33.
30. Gottesman MM, Pastan I. Multidrug resistance - a review. Ann Rev Biochem 1993; 62: 385-427.
31. Deuchars KL, Ling V. p-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989; 16: 156-65.
32. Schneider J, Bak, M, Efferth T, Kaufmann M, Mattern J. Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989; 60: 815-8.
33. Twentyman PR. Approaches to the circumvention of cytotoxic drug resistance. Haematol Rev 1990; 4: 65-74.
34. Peters LJ, Brock WA, Chapman JD, Wilson GD. Predictive assays of tumour radiocurability. Am J Clin Oncol (CCT) 1988; 11: 275-87.
35. Hill RP. Cellular basis of radiotherapy. In Tannock I. Hill RP (eds) The Basic Science of Oncology (2nd edn). McGraw-Hill, 1992: 259-75.